

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A Mendelian Randomization analysis highlights tentative relevance of diabetes-related traits

Shitao RAO^{1*}, Alexandria LAU^{1*} and Hon-Cheong SO^{1-6^}

¹School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

²CUHK Shenzhen Research Institute, Shenzhen, China

³KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China

⁴Department of Psychiatry, The Chinese University of Hong Kong, Shatin, Hong Kong

⁵Margaret K.L. Cheung Research Centre for Management of Parkinsonism, The Chinese University of Hong Kong, Shatin, Hong Kong

⁶Brain and Mind Institute, The Chinese University of Hong Kong, Shatin, Hong Kong

**these authors contributed equally to this work*

^Corresponding author

Correspondence to: Hon-Cheong So, Lo Kwee-Seong Integrated Biomedical Sciences Building, The Chinese University of Hong Kong, Shatin, Hong Kong. Tel: +852 3943 9255; E-mail: hcsso@cuhk.edu.hk

Abstract

Objectives COVID-19 has become a major public health problem. There is good evidence that ACE2 is a receptor for SARS-CoV-2, and high expression of *ACE2* may increase susceptibility to infection. We aimed to explore risk factors affecting susceptibility to infection and prioritize drug repositioning candidates, based on Mendelian randomization(MR) studies on *ACE2* lung expression.

Methods We conducted a phenome-wide MR study to prioritize diseases/traits and blood proteins causally linked to *ACE2* lung expression in GTEx. We also explored drug candidates whose targets overlapped with the top-ranked proteins in MR, as these drugs may alter *ACE2* expression and may be clinically relevant.

Results The most consistent finding was tentative evidence of an association between diabetes-related traits and increased *ACE2* expression. Based on one of the largest GWAS on type 2 diabetes(T2DM) to date($N=898,130$), T2DM was causally linked to raised *ACE2* expression($p=2.91E-03$;MR-IVW). Significant associations(at nominal level; $p<0.05$) with *ACE2* expression was observed across multiple DM datasets and analytic methods, for type 1 and 2 diabetes and related traits including early start of insulin. Other diseases/traits having nominal significant associations with increased expression included inflammatory bowel disease, (ER+)breast and lung cancers, asthma, smoking and elevated ALT. We also identified drugs that may target the top-ranked proteins in MR, such as fostamatinib and zinc.

Conclusions Our analysis suggested that diabetes and related traits may increase *ACE2* expression, which may influence susceptibility to infection(or more severe infection). However, none of these findings withstood rigorous multiple testing corrections(at $FDR<0.05$). Proteome-wide MR analyses might help uncover

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

mechanisms underlying *ACE2* expression and guide drug repositioning. Further studies are required to verify our findings.

Introduction

Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, has resulted a pandemic affecting more than a hundred countries worldwide (1-3). More than 2 million confirmed cases have been reported worldwide as at 22 Apr 2020 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>), while many mild or asymptomatic cases may remain undetected. Considering the severity of the outbreak, it is urgent to seek solutions to control the spread of the disease to susceptible groups, and to identify effective treatments. A better understanding of its pathophysiology is also urgently needed.

Notably, recent studies showed that over one quarter of confirmed cases had a history of comorbid conditions, such as hypertension, diabetes, cardiovascular disease and respiratory diseases (Table S1) (2-4). In addition, the severity of disease is likely to be higher in patients with chronic conditions(2). However, it is unclear whether such comorbidities are *causally* related to increased susceptibility, and if so, what the underlying mechanisms may be. Confounding bias (e.g. by age, sex, comorbidities, medications received, smoking/drinking history etc.) may lead to spurious associations that preclude conclusions about causality. Establishing causality is important as this is closely related to the effectiveness of interventions. If a risk factor is *causally* related to an outcome, then interventions on the risk factor will lead to reduced risks of the outcome, which may not be true for associations per se.

Based on analysis of potential receptor usage and the released sequences of SARS-CoV-2, Wan *et al.* proposed that the host receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2). Virus infectivity studies on HELA cell lines further confirmed that ACE2 is a cellular entry receptor for SARS-CoV-2 (8). Another line of evidence came from structural study of SARS-CoV-2. Wrapp *et al.* observed that the ACE2 protein could bind to the SARS-CoV-2 spike ecto-domain with high affinity (9). Importantly, ACE2 has previously been established a receptor for SARS-CoV (6; 7). Taken together, the above provide strong evidence that ACE2 is a key receptor of the novel coronavirus.

A number of studies have looked into the relationship between ACE2 expression level and coronavirus infection. For example, it was found that overexpression of ACE2 protein lead to more efficient SARS-CoV replication, which was blocked by anti-ACE2 antibodies in a dose-dependent manner (6). Two further studies also showed that susceptibility to SARS-CoV infection was correlated with ACE2 expression in cell lines (10) (11). It is therefore reasonable to hypothesize that ACE expression also affects susceptibility to SARS-CoV-2 infection. Revealing diseases/traits causally associated with altered ACE2 expression may shed light on why certain individuals are more susceptible to SARS-CoV-2 infection (or more severe infections) and the underlying mechanisms (whether the increased susceptibility is mediated via ACE2).

In this study, we wish to answer the following question: what conditions or traits may lead to increased *ACE2* expression, which may in turn result in higher susceptibility to SARS-CoV-2 infection? Here we conducted a phenome-wide Mendelian randomization (MR) study to explore diseases/traits that may be *causally* linked to increased *ACE2* lung expression. Our study is *different* from most existing MR studies: instead of considering a disease as outcome, the outcome measure is *ACE2* expression, interpreted as a surrogate for susceptibility to infection, and the exposures tested are diseases/traits. While a number of tissues may also be affected by SARS-CoV-2(12), pneumonia is a common and major complication of the disease(3), hence we focused on lung expression in this study. Regarding our study approach, phenome-wide MR is a data-driven approach which has been performed in other contexts as a powerful way to uncover unknown causal risk factors for diseases (13-15). This approach allows multiple risk factors or outcomes to be studied simultaneously. MR makes use of genetic variants as “instruments” to represent the exposure of interest, and infers causal relationship between the exposure and outcome (16). In general, MR is not affected by reverse causality (17), as genetic variants are fixed at conception (which precedes the outcome). MR is also less susceptible to confounding bias compared to conventional case-control/cohort studies, as genetic instruments are usually less strongly associated with environmental exposures than ordinary risk factors(18) (please also refer to Supplementary Text for more detailed descriptions).

In addition to diseases, as a secondary analysis, we also studied serum/plasma proteins as exposure, as they may point to potential molecular mechanisms underlying *ACE2* expression and may serve as potential predictive or prognostic biomarkers. Such proteome-wide studies may help to reveal drug repositioning candidates (19), through the search for drugs that target the top-ranked proteins. For example, if a protein causally increases the risk of a disease, then by the definition of causality, blocking the protein will lead to reduced disease risks. By finding plasma/serum proteins *causally* linked to *ACE2* expression, one may find drugs altering *ACE2* expression, which in turn may be useful for treatment.

Methods

Genome-wide association study (GWAS) data

All GWAS data are extracted from publicly available databases, which are detailed below.

Exposure data

Most GWAS data employed were based on predominantly European samples, and proper correction for population stratification has been performed. Please also refer to Table S2a/2b for details on the ethnic composition and methods to account for population stratification for GWAS included in this work.

To perform the phenome-wide study, here we made use of the latest IEU (Integrative Epidemiology Unit of University of Bristol) GWAS database (<https://gwas.mrcieu.ac.uk/>), which contains up to 111,908,636,549 genetic associations from 31,773 GWAS summary datasets (as at 26th Feb 2020). Details of each GWAS

study may be retrieved from <https://gwas.mrcieu.ac.uk/datasets/>. The database was retrieved *via* the R package “TwoSampleMR” (ver 0.5.1). MR analysis was conducted with the same package. Due to the extremely huge number of traits in the database, we performed some pre-selection to the list of traits/diseases before full analysis.

Briefly, we selected the following categories of traits: **(1)** Traits listed as priority 1 (high priority) and labelled as “Disease” or “Risk factor” (81 and 71 items respectively); **(2)** traits labelled as “protein” [3371 items originally studied in ref(20; 21)]; **(3)** (selected) traits from the UK Biobank (UKBB), as it is one of the largest source of GWAS data worldwide ($N\sim 500,000$). We consider that a proportion of traits have presumably low prior probability of association with respiratory infections, and others are less directly clinically relevant. To reduce computational burden and for ease of interpretation, a proportion of UKBB traits were filtered. More specifically, we excluded GWAS data of diseases or traits related to the following: eye or hearing problems, orthopedic and trauma-related conditions (except autoimmune diseases), skin problems (except systemic or autoimmune diseases), perinatal and obstetric problems, operation history, medication history (as confounding by indication is common and may affect the validity of results (22)), diet/exercise habit (as accuracy of information cannot be fully guaranteed and recall bias may be present), other socioeconomic features (such as type of jobs). A total of 425 UKBB traits were retained for final analysis under the third category. GWAS of blood proteins and UKBB traits were restricted to European samples.

GWAS of UKBB were based on analysis results from the Neale Lab (<https://sites.google.com/broadinstitute.org/ukbbgwasresults/>) and from MRC-IEU. GWAS analysis was performed using linear models with adjustment for population stratification; details of the analytic approach are given in: https://github.com/Nealelab/UK_Biobank_GWAS/tree/master/imputed-v2-gwas, <http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas> and <https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaeigi>. For binary outcomes, we converted the regression coefficients obtained from the linear model to those under a logistic model, based on methodology presented in (23). The SE under a logistic model was derived by the delta method (equation 37 in (23)).

Outcome data

The outcome was pulmonary expression of *ACE2*. While ideally one should study the protein expression in the lung, such data is scarce and corresponding genotype data (required for MR) is not available. Here we focus on the gene expression of *ACE2* in the lung ($N=515$). We retrieved GWAS summary data from the Genotype-Tissue Expression (GTEx) database (with API); it is one of the largest databases to date with both genotype and expression data for a large variety of tissues. The majority of the GTEx samples are European in ancestry (~85%); other ancestries included African Americans, Asians and American Indians (Table S2a). Population stratification was controlled by inclusion of principal components in genetic association analysis. For further details of GTEx please refer to (24); the eQTL analysis procedure is described in <https://gtexportal.org/home/documentationPage#staticTextAnalysisMethods>.

Mendelian randomization (MR) analysis

Here we performed two-sample MR, in which the instrument-exposure and instrument-outcome associations were estimated in different samples.

Instrument SNP selection

MR was performed on (approximately) independent SNPs with r^2 threshold of 0.001, following default settings in the R package TwoSampleMR. SNPs passing genome-wide significance ($p < 5e-8$) were included as instruments. Clinical traits or blood proteins were treated as exposures, and we used the ‘extract_instruments’ function in TwoSampleMR to retrieve SNPs for each trait from corresponding GWAS. The source GWAS for each exposure are listed in Table S2. Only SNPs with available SNP-exposure and SNP-outcome association data were retained.

MR methods

We conducted MR primarily with the ‘inverse-variance weighted’ (MR-IVW) (25) and Egger regression (MR-Egger) (26) approaches, which are among the most widely used MR methods. For exposure with only one instrument, the Wald ratio method was used. For analysis with < 3 genetic instruments, we employed MR-IVW only since MR-Egger cannot be reliably performed. The intercept from MR-Egger was used to evaluate presence of significant directional (imbalanced) horizontal pleiotropy.

For selected traits with at least nominally significant associations by MR-IVW or MR-Egger ($p < 0.05$), we also performed further analysis by GSMR (Generalised Summary-data-based Mendelian Randomisation), weighted median (an ‘implicit’ outlier-removal method (30)) and MR-RAPS. GSMR also accounts for correlated SNPs and removes likely pleiotropic outliers(27).

We tried several r^2 thresholds (0.001, 0.05, 0.1, 0.15, 0.2) for GSMR analysis on diabetes based on Mahajan et al.(28) (see Results/Table 2). SNP correlations were derived from 1000-Genomes European samples. MR-RAPS(29) is another methodology which takes into account multiple weak instruments by a robust procedure; we employed a more relaxed p-value threshold for SNP selection (0.01) for this method. One of the major concerns of MR is horizontal pleiotropy, in which the genetic instruments have effects on the outcome other than through effects on the exposure. MR-Egger, GSMR, weighted median and MR-RAPS are able to provide valid MR estimates under pleiotropy subject to certain assumptions (see ref (30) and supplementary text).

Heterogeneity among the MR estimates across individual SNPs may indicate problems related to violation of instrumental variable assumptions. One of the most notable problems is that one or more SNPs may be showing horizontal pleiotropy (30; 31). The Cochran’s Q statistic and the MR-PRESSO global test (32) were employed to test for heterogeneity for nominally significant MR findings.

Interpretation of effect sizes from MR

Regarding the effect sizes of causal associations, if the exposures were binary, the regression coefficients (beta) from MR may be roughly interpreted as average change in the outcome (per SD increase in normalized *ACE2*

expression levels) per 2.72-fold increase in the prevalence of the exposure (37). For continuous exposures, the MR estimates are average changes in outcome per unit increase of exposure (see Table S2a for the units).

Plasma/serum proteins as exposure and further analysis

In addition to MR analysis on individual plasma/serum proteins, we also performed pathway analysis by ClueGO(33). Hypergeometric tests were conducted on the top-ranked proteins (with $p < 0.05$). As an exploratory analysis, we also searched for drugs with targets overlapping with the top-ranked proteins. Drug targets were defined based on the DrugBank database. Our aim is to uncover drug candidates leading to alteration of *ACE2* expression, which may be therapeutically relevant.

Multiple testing correction

We employed a false discovery rate (FDR) approach to multiple testing correction. It controls the expected proportion of false positives among the hypothesis declared significant. FDR is also valid under positive dependency of tests (34).

The FDR in fact depends on the overall fraction of truly null hypothesis, or π_0 . It can also be considered as the prior probability that a null hypothesis is true. In reality, π_0 may vary for different subgroups of hypotheses. For instance, in our analyses, one may expect different π_0 for diseases/exposures of different kinds. Previous studies (see Table S1) suggested that some chronic disease patients are more likely affected by the infection. To address the above problem, we adopted an FDR control procedure that accounts for varying prior probabilities of association (i.e. different π_0) among different types of hypotheses. The procedure is ‘objective’ in the sense that it estimates π_0 based on the data automatically, without the need to specify π_0 by the researcher. We employed the methodology ‘FDR regression’ proposed in (35), and the R program by the author[FDRreg(ver 0.2)]. In brief, we divided our hypothesis based on the type of exposure/disease (e.g. respiratory, cardiovascular diseases etc.). These categories served as predictors or covariates, which can be used as input by FDRreg in a regression to estimate the π_0 of each hypothesis test. We also computed the significance of each predictor; it indicates which categories predicted non-null associations better than chance. For input into FDRreg, we took the results from MR-IVW unless the Egger intercept has $p < 0.05$.

Results

Please note that all supplementary tables are available at

<https://drive.google.com/open?id=1XQU7go8Ycz3V1MdeJbzO81erzkAGPib>

MR analysis for diseases and clinically relevant traits

MR results are presented in Tables 1 and 2 (full results shown in Tables S3 and S4). Traits were shown in main tables if MR-IVW or MR-Egger showed nominally significant ($p < 0.05$) results, and if the number of instrument SNPs ≥ 3 (such that pleiotropy can be assessed and results are more informative).

Overall speaking, 25 traits showed associations with *ACE2* expression at $FDR < 0.2$ and 10 had $FDR < 0.1$ (Table S4). No MR results showed $FDR < 0.05$. There were 68 nominally significant ($p < 0.05$) associations based on MR-IVW and 9 based on MR-Egger. Many significant findings were concentrated on traits related to diabetes.

Diabetes-related traits

Remarkably, a number of top-ranked results were related to diabetes. We observed totally five diabetes-related traits that showed nominally significant MR results with $FDR < 0.1$; they were all positively associated with *ACE2* expression. Three are related to diagnosis of diabetes (including both type 1 and 2) in the UKBB. Both doctor-diagnosed diabetes and self-reported diabetes in the UKBB, which presumably composed of mainly type 2 diabetes mellitus (T2DM), were significantly associated with higher *ACE2* expression (MR-IVW $p=0.0152$ and 0.0343 ; $FDR=0.0547$ and 0.0667 respectively). Another finding (id: ieu-a-23) was based on a trans-ethnic meta-analysis on T2DM in 2014 (38) (MR-IVW $p=0.0421$; $FDR=0.0748$), which had no overlap with the UKBB sample. The finding of a (nominally) significant result in this dataset can therefore be considered as an independent replication of the UKBB result.

We also observed that starting insulin within one year of diagnosis, which was only assessed within diabetic patients, was causally associated with increased *ACE2* expression (MR-IVW $p=0.031$; $FDR=0.061$). Early use of insulin may indicate type 1 diabetes (T1DM) as the underlying diagnosis or more severe/late-stage disease for T2DM patients (39). We also observed that as a whole, diabetes-related traits were significantly associated with higher probability of having non-null associations with *ACE2* expression ($p=0.026$; Table S7), based on FDRreg. No evidence of significant directional pleiotropy was observed in the above results (Egger intercept $p > 0.05$). We therefore primarily reported the results from MR-IVW, as generally the SE of causal estimates is larger with MR-Egger (36) (hence power is much weaker).

In view of the consistent causal associations with diabetes or related traits, we further searched for GWAS summary statistics that have not been included in the IEU GWAS database. We found another publicly available dataset from the DIAGRAM Consortium, based on a recent meta-analysis of T2DM by Mahajan et al. (28) based on European samples ($N=898,130$). For a more in-depth analysis, we also employed GSMR at various r^2 thresholds and MR-RAPS in addition to IVW and Egger. The full results are presented in Table 2 (also see Supp. Figures). Reassuringly, with the exception of MR-Egger (which is less powerful (36)), all other methods showed (at least nominally) significant results. For GSMR which accounts for correlated SNPs, it showed significant results consistently across different r^2 thresholds (lowest $p=9.74E-18$; r^2 threshold=0.2). While this study(28) has partial overlap with the trans-ethnic analysis in 2014 (38), the consistent associations provide further support to a causal link between diabetes and expression of *ACE2*.

We note that the Egger intercept p -value was borderline ($p=0.0545$), which may raise some concern for pleiotropy. However, we have conducted multiple tests for directional pleiotropy, so false positive findings are possible. The corresponding FDR was 0.999 for this test, if multiple testing was taken into account (573 items). We did not find any evidence of heterogeneity based on Cochran's Q (Heterogeneity $P_{IVW}=0.431/P_{Egger}=0.486$) or MR-PRESSO global test ($p=0.418$). To further compare MR-IVW and Egger models, we followed the 'Rucker framework' proposed in (30; 40), and computed the improvement in model heterogeneity by using MR-Egger. The difference was small and non-significant ($Q_{IVW}=197.77$; $Q_{Egger}=196.06$; difference=1.71; $p=0.191$), indicating MR-IVW is a reasonably good fit for the data.

For T2DM or self-reported diabetes from UKBB (which presumably comprised mainly T2DM), the causal estimates ranged from ~ 0.162 to 0.210 . The causal estimate from type 1 diabetes was slightly lower and estimated to be ~ 0.1006 .

Other diseases/traits

As shown in Table 1, a number of other diseases/traits also showed (nominally) significant results. Several neoplasms, such as breast and lung cancer, may be associated with increased *ACE2* expression. We also observed that several autoimmune disorders, especially inflammatory bowel diseases may be causally associated with *ACE2* expression. Interestingly, asthma and tobacco use also showed nominal significant associations with higher *ACE2* expression. As for other traits, high alanine aminotransferase (ALT), commonly associated with liver diseases, may be related to elevated *ACE2* expression. Other commonly measured blood measures that may lead to altered *ACE2* expression also included red cell distribution width (often associated with iron-deficiency, folate or B12 deficiency anemia), basophil percentage (inverse relationship), calcium level, urate level, HDL- and LDL-cholesterol (inverse relationship). Note that the FDR is dependent upon the category to which a trait belongs; for example, diabetes-related and autoimmune diseases showed lower FDR, likely because these types of diseases had more significant associations in general. As a tradeoff, other traits/diseases, although having nominally significant results, may have higher FDR. FDR provides an additional reference to guide prioritization of the findings; however, FDR estimation is subject to variability and should not be considered as an absolute guide. Other traits with at least nominal significance may still be worthy of further studies especially if supported by clinical observation or other evidence.

For traits showing nominally significant findings (Table 1), we have also performed other additional analyses. We do *not* observe significant heterogeneity in MR estimates across SNPs (by IVW/Egger) for most traits, except one related to lung cancer (ukb-d-C3). The MR-PRESSO global test was also *non*-significant for all traits, supporting a lack of heterogeneity. This lack of heterogeneity suggests that substantial horizontal pleiotropy is not very likely. The weighted median estimator supports associations for a subset of traits, including three diabetes-related traits (ukb-b-10694, ieu-a-23, ukb-b-8388). The GSMR method, which

removes pleiotropic outliers, is generally consistent with IVW findings (SNPs clumped at $r^2=0.001$ for both GSMR/IVW).

MR results with plasma/serum proteins as exposure

Full results are shown in Table S3 and S4 and the enriched pathways are shown in Table 3 and Table S5. Since a large number of proteins are involved, we only highlight a few top pathways here. Some of top pathways include cytokine and cytokine receptor interaction, VEGFA-VEGF2 signaling pathway, JAS-STAT signaling pathway etc. Table 4 and S6 show the list of drugs whose targets overlap with the top-ranked proteins. Note that the tables do *not* explicitly discern the direction of effects of the drugs. A few drugs target more than one protein. If they are ranked by the number of proteins targeted, the top drugs are fostamatinib, copper, zinc and zonisamide, which target ≥ 3 proteins.

Discussions

In this study we have employed Mendelian Randomization (MR) to uncover diseases/traits that may be causally linked to *ACE2* expression in the lung, which in turn may influence susceptibility to the infection. MR is a relatively well-established technique in evaluating causal relationships, and the wide availability of GWAS data enables many different exposures to be studied in the same time.

Diseases/traits causally linked to ACE2 expression

From our analysis, the most consistent finding was the tentative causal link between diabetes (and related traits) with *ACE2* expression, which was supported by multiple datasets and different analytic approaches. Other results were more tentative, but may be worthy of further studies. For example, several neoplasms (e.g. breast and lung cancers) and autoimmune diseases, elevated ALT, asthma and smoking all showed nominally significant and positive associations with *ACE2* expression.

Some of these findings were supported by previous studies. A number of COVID-19 cases (~5.4% from Table S1) were comorbid with diabetes mellitus (DM). This proportion is only a rough estimate since mild or asymptomatic cases may remain undetected. Notably, DM has been reported to be associated with poorer outcomes among infected patients (41). Similarly, DM was also common in patients infected with MERS-CoV (42; 43). Kulcsar *et al.* built a mouse model susceptible to MERS-CoV infection and induced T2DM using a high-fat diet. They found that, if affected by the virus, these diabetic mice suffered from a prolonged phase of disease and delayed recovery, possibly due to a dysregulated immune response (44). Regarding comorbidity with cancers, Liang *et al.* recently carried out a nationwide analysis of 1,590 patients with confirmed COVID-19 and suggested that cancer patients have higher infection and complication risks than those without (45).

We highlight a few research directions of interest, if our findings are confirmed in future studies. For example, as far as treatment is concerned, if certain conditions (e.g. diabetes) increase susceptibility to infection or severe infections via *ACE2*, drugs targeting this gene/protein may be particularly useful for this patient subgroup. For example, human recombinant *ACE2* has been proposed as a treatment and is under clinical trial

(46; 47). It will be interesting to see if the drug may be more beneficial for DM patients. More generally speaking, if DM is causally linked to elevated *ACE2* and potentially increased susceptibility to infection, then anti-diabetic drugs or improved glycemic control may ameliorate the process. Interestingly, a recent work highlighted metformin as one of the top repositioning candidates for COVID-19, based on a different mechanism as an MRC1 inhibitor (48). From a public health perspective, identification of at-risk populations may guide prevention strategies, e.g. prioritization of groups to receive vaccination. Nevertheless, all the above require substantial additional research before clinical applications.

On ACE2 expression and pulmonary complications

As discussed above, increased expression of *ACE2* appears to correlate with susceptibility to SARS-CoV and SARS-CoV-2 infection. Nevertheless, the consequences of altered *ACE2* expression on pulmonary complications may be rather complex. Kuba *et al.* reported that SARS-CoV down-modulated *ACE2* expression (7), which may lead to heightened risks of acute lung injury (ALI). Another study (49) suggested *ACE2* may protect against ALI by blocking the renin-angiotensin pathway. However, whether the same applies to SARS-CoV-2 is unknown. If this is the case, one may hypothesize that for *unaffected* individuals or those without (or with minimal) lung involvement yet, *lower ACE2* pulmonary expression may be beneficial in reducing susceptibility to more sustained infection by reducing viral entry. However, for patients with severe lung involvement or at risk of ALI, *higher ACE2* expression may prevent acute respiratory failure. Therefore, it may be clinically relevant to identify both risk factors/drugs leading to increased and decreased *ACE2* expression. Further studies are warranted to clarify the role of *ACE2* in COVID-19 and related complications.

Another related controversy concerns the use of ACE inhibitors (ACEI) and angiotensin II receptor blockers (ARB) (50; 51), although the present study does not directly address this issue. There is some evidence that ACEI/ARB may upregulate *ACE2* expression in the heart (52), kidney (53) and aorta (54) in animal models, however how these drugs affect pulmonary *ACE2* levels in humans is still unclear (55). In addition, it is possible that patients' other underlying conditions may affect *ACE2* expression. It is worthy to further investigate how ACEI/ARB together with other chronic conditions affects the risks and severity of infection.

Highlight of tentative repositioning candidates based on blood proteins potentially linked to ACE2 expression

The drugs we highlighted in this study may help researchers to *prioritize* repositioning candidates for further studies, given the huge cost and long time in developing a brand-new drug. Nevertheless, the overall direction and magnitude of effect of each drug could not be determined from our analysis alone, hence further studies are required. Here we briefly highlight a few top candidates. *Fostamatinib* targets the largest number (seven) of proteins potentially linked to *ACE2* expression. According to DrugBank, it serves as an inhibitor for all these proteins, and all were linked to elevated *ACE2* expression except one. Interestingly, a recent computational repositioning study (56; 57) identified baricitinib, a JAK 1/2 and AAK1 inhibitor approved for rheumatoid arthritis (RA) as a top candidate. *Fostamatinib* is a spleen tyrosine kinase inhibitor but also inhibits JAK 1/2 and AAK1 (from DrugBank) (58) and can be used to treat RA (59). JAK-STAT signaling was also among the

top 10 pathways enriched for top proteins affecting *ACE2* expression. Interestingly, fostamatinib was reported to be effective for type 1 diabetes (60). Another candidate highlighted in (56), sunitinib, was also top-listed by our analysis. *Zinc* is also a top-listed candidate, which was reported to reduce risks of lower respiratory tract infections (61), but the evidence is not firm. Interestingly, a study in rat tissues showed reduction of ACE2 activity by zinc (62). Zinc and zinc-ionophores may inhibit SARS-CoV as shown in experimental studies (63). Zinc was recently suggested for clinical trials for COVID-19, although there is no clinical evidence yet (clinicalTrials.gov NCT04342728, NCT04326725, NCT04351490, ref(64)). As for the enriched pathways for top-ranked proteins affecting *ACE2* expression, they are discussed in Supplementary Text.

Limitations

We wish to emphasize that we consider this work as largely an *exploratory* rather than confirmatory study. As such, the findings might not be immediately applicable clinically. Our main purpose is to *prioritize* diseases, traits or proteins with potential causal links with *ACE2* expression. There are several limitations in our analysis. A major limitation is that the sample size for GTEx is relatively modest ($N = 515$), which limits the power of MR analysis. However, to our knowledge, GTEx is one of the largest databases with both genotype and expression data. We note that many associations were relatively modest, with no results showing $FDR < 0.05$, although 25 had $FDR < 0.2$. On the other hand, we examined the consistency of the observed associations across different datasets, and considered those supported by more than one set of data (e.g. diabetes-related traits) as relatively more robust, similar to the approach in (65). However, our findings will require further support by further studies. Besides, some results could be false negatives owing to limited power. Besides, while most GWAS were based on predominantly European samples, subjects of other ethnicities were included in some samples. It is possible for genetic associations to differ across ethnicities, which may affect the causal estimates of MR, for example if some SNP-exposure or SNP-outcome associations are stronger in one ethnic group than another. Apart from the above, this study does *not* address what factors may aggravate or ameliorate *CoV-induced* changes in *ACE2* levels. Also, we studied *ACE2* mRNA expression as the outcome; associations of the reported traits with protein expression levels remain to be investigated.

Finally, from a methodological point of view, we have employed MR in a different manner from most other studies. Usually MR is used to identify causal risk factors with a disease as the outcome, for which GWAS data is available. Here we presented a novel analytic approach: we made use of existing knowledge of a key receptor of an infectious agent to uncover causal risk factors and repositioning candidates. This analytic framework may also be applied to other diseases, especially when a target can be identified but genomic data for the disease is limited, or if one is interested in the underlying disease mechanism of the risk factor.

Conclusions

Notwithstanding the limitations, we have identified several diseases and traits which may be causally related to *ACE2* expression the lung, which in turn may mediate susceptibility to SARS-CoV-2 infection. In addition, our proteome-wide MR analysis revealed proteins that could lead to changes in *ACE2* expression.

Subsequent drug repositioning analysis highlighted several candidates that may warrant further investigations. We stress that most of the findings require validation in further studies, especially the part on repositioning. Nevertheless, we believe this work is of value in view of the urgency to address the outbreak of COVID-19.

Acknowledgements

We would like to thank Prof. Stephen Tsui for computing support. This study was partially supported by the Lo Kwee Seong Biomedical Research Fund, an NSFC grant (81971706) and a Chinese University of Hong Kong Direct Grant. We also thank Mr. Carlos Chau for assistance in part of the analysis.

Author contributions

Conceived and designed the study: HCS (lead), with input from SR. Supervised the study: HCS. Data analysis: HCS (lead), SR, AL. Data interpretation: HCS, SR, AL. Drafted the manuscript: HCS (lead), with input from AL and SR.

Conflicts of interest

The authors declare no conflict of interest.

Table 1. Overall MR analysis results achieving nominal significance ($p < 0.05$), with diseases/traits as exposure and *ACE2* lung expression as outcome.

id	trait	nsnps	b_	pval_	b_	pval_	Egger_	pval_	b_	pval_	b_	pval_	FDR	pval_het_	pval_het_	P_global_
			IVW	IVW	Egger	Egger	intercept	intercept	median	median	gsmr	gsmr		IVW	Egger	PRESSO
<i>Diseases as exposure</i>																
<u>Diabetes-related</u>																
ukb-b-10753	Diabetes diagnosed by doctor	58	0.175	0.015	0.002	0.988	0.020	0.225	0.146	0.183	0.171	0.017	0.055	0.350	0.379	0.304
ukb-b-12948	Non-cancer illness code, self-reported: diabetes	49	0.162	0.034	0.203	0.255	-0.005	0.797	0.126	0.280	0.158	0.034	0.067	0.322	0.288	0.306
ukb-b-10694	Diagnoses - secondary ICD10: E10.9 Type I Diabetes mellitus without complications	3	0.101	0.042	0.184	0.428	-0.052	0.654	0.110	0.033	-	-	0.071	0.851	0.659	-
ieu-a-23	Type 2 diabetes	25	0.210	0.042	0.160	0.696	0.005	0.899	0.261	0.063	0.187	0.076	0.075	0.849	0.811	0.859
ukb-b-8388	Started insulin within one year diagnosis of diabetes	7	0.076	0.031	0.077	0.352	-0.001	0.991	0.084	0.041	-	-	0.061	0.988	0.967	0.990
<u>Neoplasms</u>																
ukb-d-D12	Diagnoses - main ICD10: D12 Benign neoplasm of colon, rectum, anus and anal canal	12	-0.286	0.015	-0.058	0.904	-0.031	0.621	-0.314	0.047	-0.331	0.007	0.930	0.865	0.815	0.873
ukb-d-C3	Malignant neoplasm of respiratory system and intrathoracic organs	3	0.514	0.009	0.711	0.511	-0.056	0.821	0.416	0.047	-	-	0.509	0.066	0.022	-
ieu-a-1134	ER+ Breast cancer (GWAS)	7	0.176	0.020	0.539	0.128	-0.094	0.259	0.122	0.224	-	-	0.272	0.547	0.645	0.497
ieu-a-1013	Glioma	3	0.200	0.037	0.438	0.659	-0.071	0.800	0.205	0.081	-	-	0.502	0.942	0.910	-
<u>Autoimmune disorders</u>																
ukb-b-18194	Non-cancer illness code, self-reported: ankylosing spondylitis	3	0.087	0.016	0.017	0.991	0.059	0.964	0.095	0.023	-	-	0.112	0.944	0.735	-

ieu-a-32	Ulcerative colitis	29	0.026	0.667	0.586	0.003	-0.105	0.003	0.099	0.240	0.026	0.626	0.054	0.171	0.629	0.165
ieu-a-292	Inflammatory bowel disease	107	0.003	0.938	0.246	0.019	-0.031	0.011	0.023	0.728	0.010	0.827	0.126	0.724	0.846	0.700
ieu-a-30	Crohn's disease	41	0.011	0.786	0.196	0.035	-0.044	0.027	0.055	0.352	0.011	0.781	0.159	0.651	0.826	0.623
ieu-a-31	Inflammatory bowel disease	49	-0.014	0.783	0.287	0.036	-0.051	0.019	0.024	0.742	-0.011	0.814	0.170	0.724	0.846	0.700
<u>Other diseases</u>																
ukb-b-17219	Diagnoses - secondary ICD10: J45.9 Asthma, unspecified	19	0.264	0.035	0.877	0.056	-0.064	0.152	0.295	0.092	0.269	0.035	0.500	0.769	0.826	0.770
ukb-b-5115	Diagnoses - secondary ICD10: Z72.0 Tobacco use	3	0.918	0.016	0.624	0.856	0.024	0.930	0.915	0.059	-	-	0.510	0.415	0.187	-
ukb-d-19	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	14	-0.269	0.024	-0.138	0.656	-0.017	0.645	-0.174	0.265	-0.264	0.028	0.934	0.886	0.858	0.900
<i>Other risk factors or clinically relevant traits as exposure</i>																
ukb-d-30620_raw	Alanine aminotransferase (U/L)	91	0.047	0.007	0.081	0.041	-0.012	0.341	0.069	0.015	0.051	0.004	0.223	0.717	0.716	0.722
ukb-d-30070_irnt	Red blood cell (erythrocyte) distribution width (SD)	225	0.243	0.020	0.349	0.066	-0.004	0.500	0.208	0.191	0.239	0.023	0.555	0.524	0.514	0.537
ukb-d-30220_irnt	Basophil percentage (SD)	77	-0.504	0.027	-0.584	0.169	0.003	0.821	-0.473	0.179	-0.468	0.045	0.935	0.535	0.504	0.558
ukb-d-30780_raw	LDL direct (mmol/L)	126	-0.272	0.105	-0.758	0.005	0.020	0.021	-0.469	0.076	-0.179	0.299	0.934	0.520	0.633	0.541
ukb-d-30680_raw	Calcium (mmol/L)	152	0.202	0.915	-10.380	0.011	0.031	0.003	-1.675	0.545	0.626	0.728	0.935	0.135	0.259	0.136
ukb-d-30830_raw	SHBG (mmol/L)	163	0.004	0.443	0.022	0.042	-0.016	0.055	0.012	0.166	0.004	0.441	0.934	0.219	0.267	0.209
ieu-a-793	Urate (mg/dl)	4	0.026	0.027	0.026	0.167	-0.008	0.884	0.028	0.037	-	-	0.608	0.792	0.603	0.382
ieu-a-1034	Height (SD)	4	0.636	0.047	2.060	0.806	-0.118	0.865	0.599	0.124	-	-	0.553	0.647	0.445	0.643
ieu-a-299	HDL cholesterol (SD)	84	0.084	0.515	0.563	0.022	-0.026	0.020	0.065	0.758	0.086	0.508	0.581	0.575	0.714	0.592

Some items are missing as the number of SNPs is insufficient. Nsnps, number of SNPS. b, beta (causal estimate); pval, p-value. IVW, inverse-variance weighted approach; median, weighted median approach; FDR, false discovery rate, derived from FDR regression; pval_het, heterogeneity p-value; P_global_PRESSO, p-value from the global test of MR-PRESSO (used to assess heterogeneity of MR estimates).

FDR refers to the p-value from MR-IVW (if Egger intercept $p > 0.05$) or MR-Egger. Values of FDR below 0.1 are in bold.

Table 2. Further MR analysis results for type 2 diabetes based on 2018 Mahajan et al.

Method	beta	se	pval	Egger Intercept	Intercept pval	n_pleio	nsnps
MR-IVW	0.177	0.060	2.91E-03	-	-	-	196
MR-Egger	-0.039	0.126	0.758	0.0159	0.0545	-	196
GSMR ¹							
$r^2=0.001$	0.170	0.060	4.46E-03	-	-	0	194
$r^2=0.05$	0.140	0.035	7.12E-05			0	289
$r^2=0.1$	0.177	0.054	9.62E-04	-	-	0	332
$r^2=0.15$	0.146	0.027	5.93E-08			0	392
$r^2=0.2$	0.197	0.023	9.74E-18			0	448
MR-RAPS ²	0.064	0.030	3.43E-02	-	-	-	3737

We did not find any evidence of heterogeneity based on Cochran's Q (Heterogeneity $P_{IVW}=0.431/P_{Egger}=0.486$) or MR-PRESSO global test ($p=0.418$). We also computed the improvement in model heterogeneity by using MR-Egger over IVW following Rucker's framework. The difference was small and non-significant ($Q_{IVW}=197.77$; $Q_{Egger}=196.06$; difference=1.71; $p=0.191$).

The exposure GWAS dataset on type 2 diabetes was based on Mahajan et al. (2018). Nature genetics, 50(11), 1505-1513. Instrument SNPs were only selected if they passed genome-wide significance ($p<5e-8$) (except for MR-RAPS). If not otherwise specified, SNPs were clumped at $r^2 = 0.001$.

1 GSMR can account for correlation among SNPs. We performed GSMR based on SNPs clumped at different r^2 clumping thresholds. We consider the association to be more robust if significant results are observed across multiple r^2 thresholds

2 MR-RAPS is an MR methodology designed for the inclusion of multiple weak instruments. A more relaxed p-value threshold (0.01) was used for SNP instrument selection.

Table 3. Top 10 enriched pathways for (nominally) significant proteins in MR analysis.

GOID	GO Term	Ontology Source	Term PVal	Term Pval (Bonf corrected)	Associated Genes
KEGG:04060	Cytokine-cytokine receptor interaction	KEGG_27.02.2019	1.82E-06	7.29E-05	[<i>CCL25, CTF1, CX3CL1, CXCL12, IL15RA, IL22, IL34, IL37, LTA, LTBR, OSM, TNFSF4, TNFSF8</i>]
WP:3888	VEGFA-VEGFR2 Signaling Pathway	WikiPathways_27.02.2019	7.79E-06	3.11E-04	[<i>ACACB, BCL2L1, CFL1, EEAI, F3, IGFBP7, JAG1, KDR, PIK3CA, PTPN1, TXNIP</i>]
WP:254	Apoptosis	WikiPathways_27.02.2019	1.07E-04	4.29E-03	[<i>BCL2L1, BIRC5, DIABLO, IGF1, LTA, MCL1</i>]
WP:3614	Photodynamic therapy-induced HIF-1 survival signaling	WikiPathways_27.02.2019	2.99E-04	1.19E-02	[<i>BCL2L1, BIRC5, HK1, MCL1</i>]
R-HSA:399954	Sema3A PAK dependent Axon repulsion	REACTOME_Pathways_27.02.2019	3.40E-04	1.36E-02	[<i>CFL1, PAK3, PLXNA1</i>]
R-HSA:2173782	Binding and Uptake of Ligands by Scavenger Receptors	REACTOME_Pathways_27.02.2019	4.89E-04	1.96E-02	[<i>FTH1, HP, STAB1, STAB2</i>]
KEGG:04630	JAK-STAT signaling pathway	KEGG_27.02.2019	5.61E-04	2.24E-02	[<i>BCL2L1, CTF1, IL15RA, IL22, MCL1, OSM, PIK3CA</i>]
KEGG:04672	Intestinal immune network for IgA production	KEGG_27.02.2019	8.84E-04	3.53E-02	[<i>CCL25, CXCL12, IL15RA, LTBR</i>]
WP:3657	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex	WikiPathways_27.02.2019	9.00E-04	3.60E-02	[<i>BCL2L1, FLT3, MCL1</i>]
WP:3872	Regulation of Apoptosis by Parathyroid Hormone-related Protein	WikiPathways_27.02.2019	0.00090	0.03602	[<i>BCL2L1, MCL1, PIK3CG</i>]

Pval, p-value; Bonf, Bonferroni correction.

Table 4. Drugs with targets overlapping with (nominally) significant proteins from MR analysis

Drug	No. of proteins targeted	Targets (that overlap with proteins with at least significance in MR analysis)
Fostamatinib	7	ZAP70 FLT3 HIPK3 KDR MST1R PAK3 PIK3CG
Copper	6	CFL1 S100A2 PARK7 AHSG APOD CBX5
Zinc	4	S100A2 AHSG C8A APLP2
Zonisamide	3	CA4 CA9 CA10
Benzthiazide	2	CA4 CA9
Hyaluronic acid	2	LAYN STAB2
Hydroflumethiazide	2	CA4 CA9
Isosorbide	2	BCL2L1 MCL1
Midostaurin	2	KDR FLT3
Nintedanib	2	KDR FLT3
Ponatinib	2	FLT3 KDR
Sodium carbonate	2	CA4 CA9
Sorafenib	2	KDR FLT3
Sunitinib	2	KDR FLT3

Direction and magnitude of the drugs' effects on *ACE2* expression cannot be determined from our analysis alone, hence are not indicated here.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *The New England journal of medicine* 2020;
2. Novel-Coronavirus-Pneumonia-Emergency-Response-Epidemiology-Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2020;41:145-151
3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui DSC, Du B, Li L-j, Zeng G, Yuen K-Y, Chen R-c, Tang C-l, Wang T, Chen P-y, Xiang J, Li S-y, Wang J-l, Liang Z-j, Peng Y-x, Wei L, Liu Y, Hu Y-h, Peng P, Wang J-m, Liu J-y, Chen Z, Li G, Zheng Z-j, Qiu S-q, Luo J, Ye C-j, Zhu S-y, Zhong N-s. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* 2020;
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395:497-506
5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of virology* 2020;
6. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003;426:450-454
7. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nature medicine* 2005;11:875-879
8. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* 2020:2020.2001.2022.914952
9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* 2020:2020.2002.2011.944462
10. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pöhlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. *Biochemical and Biophysical Research Communications* 2004;319:1216-1221

11. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB, Jr. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. *Journal of virology* 2005;79:14614-14621
12. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of medicine* 2020;
13. Langdon RJ, Richmond RC, Hemani G, Zheng J, Wade KH, Carreras-Torres R, Johansson M, Brennan P, Wootton RE, Munafo MR, Smith GD, Relton CL, Vincent EE, Martin RM, Haycock P. A Phenome-Wide Mendelian Randomization Study of Pancreatic Cancer Using Summary Genetic Data. *Cancer Epidemiology Biomarkers & Prevention* 2019;28:2070-2078
14. Li X, Meng X, He Y, Spiliopoulou A, Timofeeva M, Wei W-Q, Gifford A, Yang T, Varley T, Tzoulaki I, Joshi P, Denny JC, McKeigue P, Campbell H, Theodoratou E. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. *PLOS Medicine* 2019;16:e1002937
15. Meng X, Li X, Timofeeva MN, He Y, Spiliopoulou A, Wei WQ, Gifford A, Wu H, Varley T, Joshi P, Denny JC, Farrington SM, Zgaga L, Dunlop MG, McKeigue P, Campbell H, Theodoratou E. Phenome-wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. *International journal of epidemiology* 2019;48:1425-1434
16. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International journal of epidemiology* 2003;32:1-22
17. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;23:R89-98
18. Smith GD, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. *PLoS Med* 2007;4:e352
19. Schmidt AF, Finan C, Gordillo-Maranon M, Asselbergs FW, Freitag D, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyzna M. Genetic drug target validation using Mendelian randomization. *bioRxiv* 2019:781039
20. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N, Spain SL, Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA, Soranzo N, Suhre K, Paul DS, Fox CS, Plenge RM, Danesh J, Runz H, Butterworth AS. Genomic atlas of the human plasma proteome. *Nature* 2018;558:73-79
21. Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Franberg M, Sennblad B, Baldassarre D, Veglia F, Humphries SE, Rauramaa R, de Faire U, Smit AJ, Giral P, Kurl S, Mannarino E, Enroth S, Johansson A, Enroth SB, Gustafsson S, Lind L, Lindgren C, Morris AP, Giedraitis V, Silveira A, Franco-Cereceda A, Tremoli E, group Is, Gyllenstein U, Ingelsson E, Brunak S, Eriksson P, Ziemek D, Hamsten A, Malarstig A. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. *PLoS genetics* 2017;13:e1006706

22. Bellera C, Proust-Lima C, Joseph L, Richaud P, Taylor J, Sandler H, Hanley J, Mathoulin-Pelissier S. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication. *Statistical methods in medical research* 2018;27:1271-1281
23. Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio. *Genetics* 2018;208:1397-1408
24. Gamazon ER, Segrè AV, van de Bunt M, Wen X, Xi HS, Hormozdiari F, Ongen H, Konkashbaev A, Derks EM, Aguet F, Quan J, Nicolae DL, Eskin E, Kellis M, Getz G, McCarthy MI, Dermitzakis ET, Cox NJ, Ardlie KG, Consortium GT. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. *Nature genetics* 2018;50:956-967
25. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic epidemiology* 2013;37:658-665
26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology* 2015;44:512-525
27. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, Yang J. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature communications* 2018;9:224
28. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup N, Cook JP, Schmidt EM, Wuttke M, Sarnowski C, Magi R, Nano J, Gieger C, Trompet S, Lecocour C, Preuss MH, Prins BP, Guo X, Bielak LF, Below JE, Bowden DW, Chambers JC, Kim YJ, Ng MCY, Petty LE, Sim X, Zhang W, Bennett AJ, Bork-Jensen J, Brummett CM, Canouil M, Ec Kardt KU, Fischer K, Kardia SLR, Kronenberg F, Lall K, Liu CT, Locke AE, Luan J, Ntalla I, Nylander V, Schonherr S, Schurmann C, Yengo L, Bottinger EP, Brandslund I, Christensen C, Dedoussis G, Florez JC, Ford I, Franco OH, Frayling TM, Giedraitis V, Hackinger S, Hattersley AT, Herder C, Ikram MA, Ingelsson M, Jorgensen ME, Jorgensen T, Kriebel J, Kuusisto J, Ligthart S, Lindgren CM, Linneberg A, Lyssenko V, Mamakou V, Meitinger T, Mohlke KL, Morris AD, Nadkarni G, Pankow JS, Peters A, Sattar N, Stancakova A, Strauch K, Taylor KD, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tuomilehto J, Witte DR, Dupuis J, Peyser PA, Zeggini E, Loos RJJ, Froguel P, Ingelsson E, Lind L, Groop L, Laakso M, Collins FS, Jukema JW, Palmer CNA, Grallert H, Metspalu A, Dehghan A, Kottgen A, Abecasis GR, Meigs JB, Rotter JJ, Marchini J, Pedersen O, Hansen T, Langenberg C, Wareham NJ, Stefansson K, Gloyn AL, Morris AP, Boehnke M, McCarthy MI. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nature genetics* 2018;50:1505-1513
29. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *arXiv preprint arXiv:180109652* 2018;
30. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* 2018;27:R195-R208
31. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. *Research Synthesis Methods* 2019;10:486-496

32. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature genetics* 2018;50
33. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pagès F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 2009;25:1091-1093
34. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. *Ann Stat* 2001;29:1165-1188
35. Scott JG, Kelly RC, Smith MA, Zhou PC, Kass RE. False Discovery Rate Regression: An Application to Neural Synchrony Detection in Primary Visual Cortex. *J Am Stat Assoc* 2015;110:459-471
36. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *European journal of epidemiology* 2017;32:377-389
37. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *European journal of epidemiology* 2018;33:947-952
38. Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukkaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W,

- Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinhorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nature genetics* 2014;46:234-244
39. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. *Lancet Diabetes Endocrinol* 2018;6:122-129
40. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* 2017;36:1783-1802
41. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, Liu X-Q, Chen R-C, Tang C-L, Wang T, Ou C-Q, Li L, Chen P-Y, Sang L, Wang W, Li J-F, Li C-C, Ou L-M, Cheng B, Xiong S, Ni Z-Y, Xiang J, Hu Y, Liu L, Shan H, Lei C-L, Peng Y-X, Wei L, Liu Y, Hu Y-H, Peng P, Wang J-M, Liu J-Y, Chen Z, Li G, Zheng Z-J, Qiu S-Q, Luo J, Ye C-J, Zhu S-Y, Cheng L-L, Ye F, Li S-Y, Zheng J-P, Zhang N-F, Zhong N-S, He J-X, China Medical Treatment Expert Group for C. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* 2020:2000547
42. Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. *Virologica Sinica* 2016;31:81-84
43. Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, Alanazi MS, Mohamed N, Alrasheed MM, Abanny N, Alhawassi T. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. *Epidemiology and infection* 2018:1-5
44. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. *JCI Insight* 2019;4:e131774
45. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *The Lancet Oncology* 2020;
46. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, del Pozo CH, Prosper F. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. *Cell* 2020;

47. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. Available at <https://ClinicalTrials.gov/show/NCT04335136>., 2020
48. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Naing ZZC, Zhou Y, Peng S, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Shen W, Shi Y, Zhang Z, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Ramachandran R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Wankowicz SA, Bohn M, Sharp PP, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Roesch F, Vallet T, Meyer B, White KM, Miorin L, Rosenberg OS, Verba KA, Agard D, Ott M, Emerman M, Ruggero D, García-Sastre A, Jura N, von Zastrow M, Taunton J, Ashworth A, Schwartz O, Vignuzzi M, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor S, Fraser JS, Gross J, Sali A, Kortemme T, Beltrao P, Shokat K, Shoichet BK, Krogan NJ. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. *bioRxiv* 2020:2020.2003.2022.002386
49. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005;436:112-116
50. Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. *Hypertension Research* 2020;
51. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? *Journal of the American Heart Association* 2020;9:e016509
52. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 2005;111:2605-2610
53. Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. *American journal of physiology Renal physiology* 2010;298:F1297-1305
54. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. *American Journal of Physiology-Heart and Circulatory Physiology* 2005;289:H1013-H1019
55. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, Hamie QM, Meier CF, Hunziker S, Forras-Kaufmann Z, Kuyumcu S, Fox M, Schwizer W, Fried M, Lindenmeyer M, Gotze O, Verrey F. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. *Amino acids* 2015;47:693-705
56. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet* 2020;395:E30-E31

57. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. *The Lancet Infectious Diseases* 2020;
58. Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. *Pharmacology research & perspectives* 2015;3:e00175
59. Kang Y, Jiang X, Qin D, Wang L, Yang J, Wu A, Huang F, Ye Y, Wu J. Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Front Pharmacol* 2019;10:897
60. Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovskiy A, Clynes R. Therapeutic targeting of Syk in autoimmune diabetes. *Journal of immunology (Baltimore, Md : 1950)* 2010;185:1532-1543
61. Roth DE, Richard SA, Black RE. Zinc supplementation for the prevention of acute lower respiratory infection in children in developing countries: meta-analysis and meta-regression of randomized trials. *International journal of epidemiology* 2010;39:795-808
62. Speth R, Carrera E, Jean-Baptiste M, Joachim A, Linares A. Concentration-dependent effects of zinc on angiotensin-converting enzyme-2 activity (1067.4). *The FASEB Journal* 2014;28:1067.1064
63. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS pathogens* 2010;6:e1001176
64. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos DA, Aaseth J. Zinc and respiratory tract infections: Perspectives for COVID-19. *International Journal of Molecular Medicine* 2020;In press.
65. Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery CL, Buyske S, Cai C, Fesinmeyer MD, Haiman C, Heiss G, Hindorff LA, Hsu CN, Jackson RD, Kooperberg C, Le Marchand L, Lin Y, Matisse TC, Moreland L, Monroe K, Reiner AP, Wallace R, Wilkens LR, Crawford DC, Ritchie MD. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. *Genetic epidemiology* 2011;35:410-422